Table 1.
Clinical trials of FGFR inhibitors
| Tumor type | Drug | Company | Target | Clinical development stage |
|---|---|---|---|---|
| Glioblastoma | BGJ398 | Novartis | FGFR1–3 | Phase II (NCT01975701) |
| AZD4547 | AstraZeneca | FGFR1–3 | Phase I/II (NCT02824133) | |
| Solid tumors/ lymphoma | E‐7090 | Eisai | FGFR1–3 | Phase I (NCT02275910) |
| LY2874455 | Eli Lilly & Co. | Pan‐FGFR | Phase I (NCT03125239) | |
| TAS‐120 | Taiho Pharm | FGFR1–4 | Phase I/II (NCT02052778) | |
| Erdafitinib (JNJ42756493) | Janssen | FGFR1–4, VEGFR2 | Phase II (NCT02421185) | |
| Rogaratinib (BAY1163877) | Bayer | FGFR1–4 | Phase II (NCT03410693) | |
| Debio‐1347 | Debio Pharm | FGFR1–3 | Phase I (NCT01948297) |